Compare GSK plc (GSK) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs VanEck Rare Earth/Strategic Metals — how do they compare? GSK plc trades at $50.33 (market cap $102.60B), while VanEck Rare Earth/Strategic Metals trades at $77.43. The key difference: GSK plc pays a 3.57% dividend while VanEck Rare Earth/Strategic Metals pays none, and GSK plc is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| GSK | REMX | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | Sector/Thematic |
52-Week High | $61.18 | $109.53 |
52-Week Low | $38.22 | $56.60 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $77.03, down 1.81% with a bullish technical signal from moving averages but neutral oscillators. The ETF provides exposure to 38 global rare earth companies, though key financial ratios remain undisclosed. Recent news highlights U.S. efforts to secure critical minerals supply chains amid China's export controls, with Energy Fuels expanding domestic production capacity.
Outlook hinges on geopolitical rare earth dynamics and U.S. supply chain independence initiatives. Risks include high volatility (~50% annualized) and China concentration. Analyst sentiment is mixed due to thematic reliance on policy shifts and commodity cycles, warranting caution for conservative investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
